The Registry to Study Safety and Performance of the CORDIS Vascular Reconstruction Device and Delivery System

Inclusion Criteria: * The subject must be \>= 18 years of age and less than 80 years. * Diagnosis of a ruptured (Hunt and Hess Grade I - III) or unruptured intracranial aneurysm at the time of the treatment * Subject (or his/her legal representative) provides written informed consent for the use of his/her peri-procedural and follow-up data Exclusion Criteria: * Diagnosis of Hunt and Hess Grade IV or V subarachnoid hemorrhage at the time of the treatment * Severe co-morbidity associated with a life-expectancy of less than six months * Poor neurological status at baseline * Known allergies to Nitinol metal * Known allergies to aspirin, heparin, ticlopidine, or clopidogrel or unable or unwilling to tolerate therapy * Participation in an investigational drug or another device study is only allowed after written approval of the coordinating investigator or Cordis Medical Monitor. * Implantation of an intracranial stent associated with the symptomatic distribution within 12 weeks prior to the index procedure * Implantation of carotid stent associated with the symptomatic distribution within 12 weeks prior to the index procedure * Atrial fibrillation or known cardiac disorders likely to be associated with cardioembolic symptoms.